These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

32 related articles for article (PubMed ID: 10708944)

  • 1. Overexpression of Hsp27 affects the metastatic phenotype of human melanoma cells in vitro.
    Aldrian S; Trautinger F; Fröhlich I; Berger W; Micksche M; Kindas-Mügge I
    Cell Stress Chaperones; 2002 Apr; 7(2):177-85. PubMed ID: 12380685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha(v)beta3 expression on blood vessels and melanoma cells in primary lesions: differential association with tumor progression and clinical prognosis.
    Kageshita T; Hamby CV; Hirai S; Kimura T; Ono T; Ferrone S
    Cancer Immunol Immunother; 2000 Aug; 49(6):314-8. PubMed ID: 10946813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic targeting of anoikis resistance in cutaneous melanoma metastasis.
    Neuendorf HM; Simmons JL; Boyle GM
    Front Cell Dev Biol; 2023; 11():1183328. PubMed ID: 37181747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and Characterization of Functionalized Graphene Oxide Carrier for siRNA Delivery.
    Li J; Ge X; Cui C; Zhang Y; Wang Y; Wang X; Sun Q
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30336549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Delivery of siRNA Therapeutics to Malignant Tumors.
    Leng Q; Woodle MC; Mixson AJ
    J Drug Deliv; 2017; 2017():6971297. PubMed ID: 29218233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Delivery of Tumor-Targeted Bax-Derived Membrane-Active Peptides for the Treatment of Melanoma Tumors in a Humanized SCID Mouse Model.
    Karageorgis A; Claron M; Jugé R; Aspord C; Thoreau F; Leloup C; Kucharczak J; Plumas J; Henry M; Hurbin A; Verdié P; Martinez J; Subra G; Dumy P; Boturyn D; Aouacheria A; Coll JL
    Mol Ther; 2017 Feb; 25(2):534-546. PubMed ID: 28153100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro and In Vivo Efficacy of Self-Assembling RGD Peptide Amphiphiles for Targeted Delivery of Paclitaxel.
    Saraf P; Li X; Wrischnik L; Jasti B
    Pharm Res; 2015 Sep; 32(9):3087-101. PubMed ID: 26063045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matched rabbit monoclonal antibodies against αv-series integrins reveal a novel αvβ3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors.
    Goodman SL; Grote HJ; Wilm C
    Biol Open; 2012 Apr; 1(4):329-40. PubMed ID: 23213423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular ultrasound imaging of early vascular response in prostate tumors irradiated with carbon ions.
    Palmowski M; Peschke P; Huppert J; Hauff P; Reinhardt M; Maurer M; Karger CP; Scholz M; Semmler W; Huber PE; Kiessling FM
    Neoplasia; 2009 Sep; 11(9):856-63. PubMed ID: 19724679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An in vivo model of melanoma: treatment with ATP.
    White N; Knight GE; Butler PE; Burnstock G
    Purinergic Signal; 2009 Sep; 5(3):327-33. PubMed ID: 19347609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solid-phase synthesis of alkanethiols for the preparation of self-assembled monolayers.
    Derda R; Wherritt DJ; Kiessling LL
    Langmuir; 2007 Oct; 23(22):11164-7. PubMed ID: 17880250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of the efficacy of an antagonist of an extracellular receptor by attachment to the surface of a biocompatible carrier.
    Wartchow CA; Alters SE; Garzone PD; Li L; Choi S; DeChene NE; Doede T; Huang L; Pease JS; Shen Z; Knox SJ; Cleland JL
    Pharm Res; 2004 Oct; 21(10):1880-5. PubMed ID: 15553236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrasonic analysis of peptide- and antibody-targeted microbubble contrast agents for molecular imaging of alphavbeta3-expressing cells.
    Dayton PA; Pearson D; Clark J; Simon S; Schumann PA; Zutshi R; Matsunaga TO; Ferrara KW
    Mol Imaging; 2004 Apr; 3(2):125-34. PubMed ID: 15296677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redirecting retroviral tropism by insertion of short, nondisruptive peptide ligands into envelope.
    Gollan TJ; Green MR
    J Virol; 2002 Apr; 76(7):3558-63. PubMed ID: 11884580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo effects of a cyclic peptide with affinity for the alpha(nu)beta3 integrin in human melanoma cells.
    Allman R; Cowburn P; Mason M
    Eur J Cancer; 2000 Feb; 36(3):410-22. PubMed ID: 10708944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents.
    Chatterjee S; Matsumura A; Schradermeier J; Gillespie GY
    J Neurooncol; 2000; 46(2):135-44. PubMed ID: 10894366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
    Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L
    Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist.
    Belvisi L; Riccioni T; Marcellini M; Vesci L; Chiarucci I; Efrati D; Potenza D; Scolastico C; Manzoni L; Lombardo K; Stasi MA; Orlandi A; Ciucci A; Nico B; Ribatti D; Giannini G; Presta M; Carminati P; Pisano C
    Mol Cancer Ther; 2005 Nov; 4(11):1670-80. PubMed ID: 16275988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrins as targets of angiogenesis inhibition.
    Westlin WF
    Cancer J; 2001; 7 Suppl 3():S139-43. PubMed ID: 11779085
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.